Company news

Moleculin Biotech, Inc. (NASDAQ:MBRX) news

Moleculin Biotech, Inc. news releases on 6ix. Latest, May 16, 2024: Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association…

Moleculin Biotech, Inc. (NASDAQ:MBRX) news

Press releases — page 3

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

Moleculin Reports Full Year 2023 Financial Results

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting

Moleculin Reports Third Quarter 2023 Financial Results

Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Moleculin Reports Second Quarter 2023 Financial Results

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast

Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023

Moleculin Reports First Quarter 2023 Financial Results

Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast

Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models

Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update

Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast

Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation

Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast

Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme